Vendor, Boston, MA
Strand Therapeutics Inc.
UEI PJ23TRKRFVB5, CAGE 8BLB2
1 award and $1,249,609 obligated between August 27, 2025 and May 18, 2026, 100% under full and open competition, against 87.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $1,249,609 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| FA864925P0501Purchase Order, August 27, 2025, Full and Open Competition After Exclusion of Sources, 87 offers | FA8649 USAF SBIR STTR Cntrctng AFRLDepartment of the Air Force | Sentinox (STX)-005: a Next-Generation Therapy for Autoimmune Disease to Sustain Force ReadinessNAICS 541715, PSC AC32 | $1,249,609 |
- Places of performance
- Massachusetts
- Product and service codes
- AC32 National Defense R&D Services; Defense-Related Activities; Applied Research
- Transactions
- 2 across 1 awards